Kenvue KVUE · USD
Consumer Staples · Personal Care Products · US listing · 🇺🇸 United States
S&P 500
19.31
-1.28%
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kenvue
From its filings with the US Securities and Exchange Commission
Kenvue is based in Summit, New Jersey and is incorporated in Delaware. Its shares trade on NYSE under the ticker KVUE. It is a member of the S&P 500. The SEC classifies its business as perfumes, cosmetics & other toilet preparations. In the fiscal year to 28 December 2025, it reported revenue of $15.12bn and net income of $1.47bn. At that date it held total assets of $27.08bn and shareholders' equity of $10.77bn.
At Kenvue, our purpose is to realize the extraordinary power of everyday care. As a global leader at the intersection of healthcare and consumer goods, we are the world’s largest pure-play consumer health company by revenue with $15.1 billion in Net sales in the fiscal year 2025. By combining the power of science with meaningful consumer insights and our digital strategy, we empower consumers to live healthier lives every day. Built on more than a century of heritage and trusted by generations, our differentiated portfolio of iconic brands—including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Nicorette®, Tylenol®, and Zyrtec®—is backed by science and recommended by healthcare professionals, which further reinforces our consumers’ connections to our brands.
Our portfolio includes Self Care, Skin Health and Beauty, and Essential Health products, allowing us to connect with consumers across North America, Asia Pacific (“APAC”), Europe, Middle East, and Africa (“EMEA”), and Latin America (“LATAM”) in their daily rituals and the moments that matter most. Our products are marketed across more than 165 countries worldwide.
Quoted from its 10-K, filed 20 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Consumer Staples
- Industry
- Personal Care Products
- Listed since
- 4 May 2023
- Employees
- 22,000
- Head office
- 1 KENVUE WAY, SUMMIT, NJ, 07901
- Incorporated in
- DE
- Classification
- Perfumes, Cosmetics & Other Toilet Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Larry MerloIndependent Chairman of the Board$479,994
- Mr. Kirk PerryInterim Chief Executive Officer, Director, since 2024$93,265
- Mr. Amit BanatiChief Financial Officer
- Mr. Anindya DasguptaGroup President, Asia Pacific
- Mr. Carlton LawsonGroup President, Europe, Middle East and Africa and Latin America$4.5m
- Mr. Jan MeurerGroup President, North America
- Ms. Meredith StevensChief Operations Officer$3.5m
- Ms. Luani AlvaradoChief People Officer
- Mr. Bernardo TavaresChief Technology and Data Officer
- Dr. Caroline TillettChief Scientific Officer
- Mr. Matthew OrlandoGeneral Counsel
- Mr. Russell DyerChief Corporate Affairs Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 86
- Environment
- 80
- Social
- 95
- Governance
- 84
- Direct emissions (scope 1)
- 56,538 t
- Energy emissions (scope 2)
- 152,261 t
- Value chain emissions (scope 3)
- 2,766,383 t
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kenvue Inc. is a consumer health company with a global footprint selling in over 165 countries.
- The company has a differentiated portfolio of well-known brands including Tylenol and Neutrogena.
- Kenvue employs 22,000 full-time employees and operates through three business segments.
Weaknesses
- The company's IPO occurred in 2023, indicating a relatively new public market presence.
- Kenvue's business segments are detailed but lack specific financial performance metrics.
- The source description treats all facts as untrusted, suggesting potential reliability issues.
Opportunities
- Kenvue's global distribution network with 114 distribution centers supports expansion opportunities.
- The company's product portfolio spans multiple health and beauty categories with diverse offerings.
- Kenvue's presence in over 165 countries provides potential for market growth in emerging regions.
Threats
- The company's IPO in 2023 may face challenges in establishing market confidence.
- The untrusted source description could lead to inaccurate public perception of the company.
- Kenvue's reliance on a limited set of well-known brands may expose it to brand reputation risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.